


## PF-03715455

<b>Cat. No.:</b>	HY-18862
<b>CAS No.:</b>	1056164-52-3
<b>Molecular Formula:</b>	C <sub>35</sub> H <sub>34</sub> ClN <sub>7</sub> O <sub>3</sub> S <sub>2</sub>
<b>Molecular Weight:</b>	700.27
<b>Target:</b>	p38 MAPK
<b>Pathway:</b>	MAPK/ERK Pathway
<b>Storage:</b>	Please store the product under the recommended conditions in the Certificate of Analysis.



### BIOLOGICAL ACTIVITY

<b>Description</b>	PF-03715455 is a potent inhaled p38 MAPK inhibitor. PF-03715455 shows some selectivity for p38 $\alpha$ over p38 $\beta$ with respective IC <sub>50</sub> values of 0.88 and 23 nM. PF-03715455 potently inhibits LPS-induced TNF $\alpha$ production in human whole blood (IC <sub>50</sub> =1.7 nM). PF-03715455 has potential for the treatment of COPD (chronic obstructive pulmonary disease) <sup>[1][2]</sup> .	
<b>IC<sub>50</sub> &amp; Target</b>	p38 $\alpha$ 0.88 nM (IC <sub>50</sub> )	p38 $\beta$ 23 nM (IC <sub>50</sub> )
<b>In Vitro</b>	PF-03715455 is a moderate inhibitor of CYP1A2, CYP2C19, and CYP2D6 and a potent inhibitor of CYP's 2C9 and CYP3A4 <sup>[2]</sup> . MCE has not independently confirmed the accuracy of these methods. They are for reference only.	
<b>In Vivo</b>	PF-03715455 treatment shows that the V <sub>ss</sub> and T <sub>1/2</sub> are 0.19 L/kg, 1 hour, respectively <sup>[2]</sup> . MCE has not independently confirmed the accuracy of these methods. They are for reference only.	
	Animal Model:	Male CD Sprague Dawley rats (300-450 g) <sup>[2]</sup>
	Dosage:	1 mg/kg
	Administration:	I.v. (Pharmacokinetic Analysis)
	Result:	The V <sub>ss</sub> , and T <sub>1/2</sub> were 0.19 L/kg, 1 hour, respectively.

### REFERENCES

- [1]. Norman P, et al. Investigational p38 inhibitors for the treatment of chronic obstructive pulmonary disease. *Expert Opin Investig Drugs*. 2015 Mar;24(3):383-92.
- [2]. Millan DS, et al. Design and synthesis of inhaled p38 inhibitors for the treatment of chronic obstructive pulmonary disease. *J Med Chem*. 2011 Nov 24;54(22):7797-814.

---

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA